Q1 Earnings Forecast for UTHR Issued By HC Wainwright

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for United Therapeutics in a research note issued to investors on Thursday, February 27th. HC Wainwright analyst A. Fein anticipates that the biotechnology company will post earnings per share of $7.07 for the quarter. HC Wainwright has a "Buy" rating and a $425.00 price objective on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics' Q2 2025 earnings at $7.39 EPS, Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.89 EPS and FY2028 earnings at $37.60 EPS.

Several other equities analysts have also recently weighed in on UTHR. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

Remove Ads

United Therapeutics Trading Down 1.1 %

Shares of NASDAQ UTHR traded down $3.30 during mid-day trading on Monday, hitting $307.68. The company had a trading volume of 423,068 shares, compared to its average volume of 444,575. The company has a market capitalization of $13.82 billion, a price-to-earnings ratio of 13.51, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics has a 1 year low of $221.53 and a 1 year high of $417.82. The stock's 50-day moving average price is $356.53 and its 200-day moving average price is $360.45.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the business earned $4.36 earnings per share.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC lifted its stake in shares of United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock valued at $234,000 after acquiring an additional 30 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after acquiring an additional 30 shares during the last quarter. Anchor Investment Management LLC lifted its stake in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 30 shares during the last quarter. Great Lakes Advisors LLC lifted its stake in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after acquiring an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after acquiring an additional 33 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares of the company's stock, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $361.95, for a total value of $3,619,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $932,745.15. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 116,464 shares of company stock valued at $42,396,244 over the last 90 days. Insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.